Author

K. Kousoulas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Dahai· 1 shared B. Breitenstein· 1 shared F. Musarrat· 1 shared G. S. Tan· 1 shared H. Dulin· 1 shared I. K. Uche· 1 shared M. McGee· 1 shared P. Rider· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Dahai

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivAug 5, 2021

A Herpes Simplex Virus Type-1-derived influenza vaccine induces balanced adaptive immune responses and protects mice from lethal influenza virus challenge.

P. Rider, H. Dulin, I. K. Uche…·R. Hai

DOI 10.1002/jmv.70067

mouseexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivApr 24, 2020

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections

F. Musarrat, V. Chouljenko, R. Nabi…·K. Kousoulas

This paper shows that nelfinavir mesylate inhibits SARS-CoV-2 S glycoprotein-mediated cell fusion, suggesting its potential as an antiviral against COVID-19.

DOI 10.1002/jmv.25985

humanstatistical model

𝕏 PostBluesky